Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Wieland

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|November 27, 2009
Arimoclomol: a potential therapy under development for ALSVeena Lanka, Scott Wieland, Jack Barber, et al.
Journal of Geophysical Research. Atmospheres : JGR|July 28, 2020
Self-Acceleration and Instability of Gravity Wave Packets: 3. Three-Dimensional Packet Propagation, Secondary Gravity Waves, Momentum Transport, and Transient Mean Forcing in Tidal WindsDavid C Fritts, Wenjun Dong, Thomas S Lund, et al.
Investigational New Drugs|November 13, 2014
Pharmacokinetic study of aldoxorubicin in patients with solid tumorsMonica M Mita, Ronald B Natale, Edward M Wolin, et al.
British Journal of Haematology|July 13, 2010
Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid TamibaroteneAmbra Di Veroli, Safaa M Ramadan, Mariadomenica Divona, et al.
Cancer|October 15, 2014
A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcomaSant P Chawla, Victoria S Chua, Andrew F Hendifar, et al.
JAMA Oncology|September 18, 2015
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical TrialSant P Chawla, Zsuzsanna Papai, Guzel Mukhametshina, et al.
Muscle & Nerve|June 14, 2008
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz, Jeremy M Shefner, Elizabeth Simpson, et al.
Neoplasia (New York, N.Y.)|November 8, 2014
Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastomaLuis Marrero, Dorota Wyczechowska, Alberto E Musto, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|November 27, 2009
Arimoclomol: a potential therapy under development for ALSVeena Lanka, Scott Wieland, Jack Barber, et al.
Journal of Geophysical Research. Atmospheres : JGR|July 28, 2020
Self-Acceleration and Instability of Gravity Wave Packets: 3. Three-Dimensional Packet Propagation, Secondary Gravity Waves, Momentum Transport, and Transient Mean Forcing in Tidal WindsDavid C Fritts, Wenjun Dong, Thomas S Lund, et al.
Investigational New Drugs|November 13, 2014
Pharmacokinetic study of aldoxorubicin in patients with solid tumorsMonica M Mita, Ronald B Natale, Edward M Wolin, et al.
British Journal of Haematology|July 13, 2010
Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid TamibaroteneAmbra Di Veroli, Safaa M Ramadan, Mariadomenica Divona, et al.
Cancer|October 15, 2014
A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcomaSant P Chawla, Victoria S Chua, Andrew F Hendifar, et al.
JAMA Oncology|September 18, 2015
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical TrialSant P Chawla, Zsuzsanna Papai, Guzel Mukhametshina, et al.
Muscle & Nerve|June 14, 2008
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz, Jeremy M Shefner, Elizabeth Simpson, et al.
Neoplasia (New York, N.Y.)|November 8, 2014
Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastomaLuis Marrero, Dorota Wyczechowska, Alberto E Musto, et al.
Pageof 1